Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Why this topic?
- Clearance (CL): definition
- Clearance: practical use
- Metabolism
- Phase I and phase II metabolism: enzymes and reactions
- Phase I and phase II metabolism: enzymes and examples
- Phase I and phase II metabolism: personalized medicine
- Excretion
- Renal excretion: clinical relevance, CKD and AKI
- Renal excretion: personalized medicine
- Take home messages
Topics Covered
- Metabolism
- Excretion
- Therapeutic window
- Clearance
- Phase I and phase II metabolic enzymes
- Covariates of activity & personalized medicine
- Renal excretion
Talk Citation
Allegaert, K. (2024, September 30). Metabolism, excretion, and therapeutic window [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 2, 2024, from https://doi.org/10.69645/SQZH8523.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose. However, off label use of medicines is discussed.
Other Talks in the Series: Key Concepts: Fundamentals of Pharmacology
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to this short
lecture on metabolism,
excretion, and the
therapeutic window.
I'm Karel Allegaert,
clinical pharmacologist
working at KU Leuven.
0:14
Why are we discussing
this topic?
It is because four
parameters are
the determinants of
concentration/time
profiles: absorption,
distribution, metabolism,
and excretion.
For information related to
absorption or distribution,
I refer to another lecture.
While in this lecture
we'll focus on
metabolism and excretion as both
are determinants of the
subsequent clearance
or elimination of
a given compound.
0:47
What is the definition
of clearance?
While in the most common setting
which means
first-order kinetics,
linear kinetics, it is the
amount of blood cleared,
so it's a volume, from the
drug in a unit of time.
This unit can be
seconds, minutes,
or hours depending
on the pattern.
While in zero-order kinetics
which means that it's
commonly in toxic or
intoxication type of settings,
things become non-linear
and then it's the amount
of drug cleared in
a unit of time.
The most common example
is ethanol as this will
shift quite fast from linear
to non-linear kinetics.
1:31
What is the practical
use of clearance?
It has to do with the
dose required to achieve
target plasma concentration and
obviously subsequent
effect at steady state.
I hereby use an
illustration using
continuous intravenous
administration of
two potential drugs.
Drug A cleared five
liters per hour,
and Drug B cleared
10 liters per hour.
If you would have
the same dose rate,
clearance will result in the
steady state concentration
and as Drug A has a lower
clearance compared to Drug B,
Drug A will have a higher
steady-state compared to
Drug B or the other way around
because Drug B is
cleared faster,
the steady-state
concentration will be lower.
Obviously, if you would
like to attain the
same concentrations,
you could still
adapt the dose rate
but at least it does illustrate
the link between the dose needed
and the clearance as present.